Bormann-Kennedy Barbara-Jean Anne's Form 4 filing
Xeris Biopharma Holdings, Inc. (XERS) · filed Dec 15, 2025
- Accession no.
- 0001635065-25-000004
- Filed
- Dec 15, 2025
- Trade date
- Dec 12, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $106.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bormann-Kennedy Barbara-Jean AnneCIK 0001635065 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Common Stock | SSaleDisposed | −15,000 | $7.09F2 | −$106,350 | 142,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.000 to $7.180, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.